Biomerica has gained approval from the UAE Ministry of Health and Prevention (MOHAP) for its Fortel prostate-specific antigen (PSA) screening test used in the early identification of prostate cancer.
Utilising a finger-prick blood sample, the test claims to generate 鈥榓ccurate鈥� outcomes within ten minutes by measuring elevated PSA levels, an early marker of the disease.
This rapid diagnostic tool aims to alleviate the strain on healthcare systems and enhance patient outcomes by enabling early identification.
Following the introduction of the EZ Detect colon disease at-home screening test in Dubai, which received government insurance reimbursement, Biomerica is currently focused on similar achievements with the Fortel test, having established partnerships with distributors and secured essential regulatory approvals in the region.
The company noted that the test has shown potential in clinical evaluations. A study demonstrated a sensitivity, specificity, and accuracy of 100%, 95%, and 97.5% respectively.
Further research conducted at Ain Shams University’s Faculty of Medicine in Egypt validated the effectiveness of the test, which achieved a sensitivity of 97.2%, a specificity of 96.2%, and an accuracy of 96.7%.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company continues to focus on delivering accessible, accurate, affordable, accurate diagnostic tools for early disease detection and treatment.
In May 2023, the company announced the validation of its inFoods IBS test for use with finger stick (capillary) patient whole blood samples for irritable bowel syndrome.
Biomerica’s portfolio continues to grow as the company develops and markets diagnostic and therapeutic products for point-of-care and clinical laboratory applications.
